6-硝基苯酞 | 610-93-5

• 物质功能分类: 化学试剂 - 有机试剂 - 硝基化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 中文名称: 6-硝基苯酞
• 中文别名: 6-硝基四氯苯酞；6-硝基-1,3-二氢异苯并呋喃-1-酮；6-硝苯酞酯
• 英文名称: 6-nitrophthalide
• 英文别名: 6-nitroisobenzofuran-1(3H)-one；6-nitro-3H-isobenzofuran-1-one；6-nitro-3H-2-benzofuran-1-one
• CAS: 610-93-5
• 化学式: C₈H₅NO₄
• mdl: MFCD00033529
• 分子量: 179.132
• InChiKey: RNWGZXAHUPFXLL-UHFFFAOYSA-N

物化性质

• 熔点：
  140-145 °C(lit.)
• 沸点：
  311.63°C (rough estimate)
• 密度：
  1.4908 (rough estimate)
• 稳定性/保质期：
  性质与稳定性： 在常温常压下，该物质不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R20/21/22,R36/37/38,R20/21/2
• WGK Germany：
  3
• 海关编码：
  2932209090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  贮存： 将密器密封后，储存在密封的主容器中，并放置在阴凉、干燥的地方。

SDS

Name:	6-Nitrophthalide 97% Material Safety Data Sheet
Synonym:
CAS:	610-93-5

Section 1 - Chemical Product MSDS Name:6-Nitrophthalide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
610-93-5	6-Nitrophthalide	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract.
Inhalation:
May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 610-93-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 140 - 145 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 179.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 610-93-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Nitrophthalide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 610-93-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 610-93-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 610-93-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

合成方法

可以采用两种合成路线来制备6-硝基四氯苯酞。第一种是以6-硝基邻苯二甲酸和乙酸酐为原料，经过脱水缩合一步反应得到该产物；另一种则是以苯酞为起始物料，通过硝化反应制备目标化合物。

具体步骤如下：

1. 在带有回流冷凝管、温度计的三口瓶中加入6-硝基邻苯二甲酸和乙酸酐。
2. 使用磁力搅拌进行反应，在103℃下使邻苯二甲酸开始溶解，随后继续升温至120℃并保持该温度反应2小时。使用薄层色谱检测反应进度，确保反应完全后停止加热。
3. 冷却反应物，过滤所得产物，并用乙醚洗涤滤饼。
4. 最后通过抽滤和烘干步骤，得到淡黄色针状晶体的6-硝基四氯苯酞。

反应信息

• 作为反应物：
  描述：

  6-硝基苯酞 在 (phthalocyaninato)iron(II) 、 二苯基硅烷 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以86%的产率得到6-氨基四氯苯酞
  参考文献：
  名称：

  铁和钯 (II) 酞菁作为还原硝基芳烃的可回收催化剂

  摘要：

  铁（II）和钯（II）酞菁已被确定为可回收的多相催化剂，用于使用二苯基硅烷/硼氢化钠作为乙醇中的氢源将芳香硝基化合物还原为相应的胺。各种可还原的官能团，如乙酰基、酯、氰基、酰胺、磺酰胺和羧酸等均具有良好的耐受性，并且该方法适用于克级规模。机理研究表明，硝基的还原通过直接（亚硝基）途径进行，可能铁或钯酞菁会激活硝基进行还原。FePc 和 PdPc 还催化二苯基硅烷/硼氢化钠和乙醇的组合产生氢气。图形摘要铁和钯（II）酞菁已被确立为一种有效的可回收催化体系，用于用绿色溶剂体系还原硝基芳烃。各种硝基取代的芳烃和杂芳烃已成功还原为相应的胺，产率非常好。本方法也已有效地适用于克级反应。

  DOI：

  10.1007/s10562-014-1269-6
• 作为产物：
  描述：

  苯酞 在 硫酸 、 potassium nitrate 作用下， 反应 2.5h， 以87%的产率得到6-硝基苯酞
  参考文献：
  名称：

  作为正电子发射断层扫描和光学成像双峰标签潜在前体的邻碘碘苄醇‒BODIPY结构的合成

  摘要：

  为了使新型潜在示踪剂从实验台到床头的快速发展，正电子发射断层扫描（PET）和光学成像（OI）的多峰示踪剂已成为一种非常有前途的工具。的确，它们结合了使用光学技术进行体外/体内临床前研究的简便性，以及使用其放射性版本的PET成像所提供的各种临床可能性。在这种情况下，已经研究了新的标签的制备，该标签可通过荧光成像检测并且潜在地适用于相应的前体的最后一步11 C-标记后的PET成像。通过链接o探索各种设计和综合-碘苄基醇和四甲基-BODIPY部分一起。其中，最有希望的结构是由市售廉价的起始原料通过五个步骤以30％的产率生产的。

  DOI：

  10.1016/j.tet.2019.130765
• 作为试剂：
  描述：

  苯酞 、 potassium nitrate 在 水 、 6-硝基苯酞 作用下， 以 硫酸 为溶剂， 反应 16.0h， 以This resulted in 136 g (crude) of 6-nitroisobenzofuran-1(3H)-one as a white solid的产率得到6-硝基苯酞
  参考文献：
  名称：

  Cyclohexyl-azetidinyl antagonists of CCR2

  摘要：

  本发明涉及公式I的化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。该发明还涉及一种预防、治疗或改善综合症、疾病或疾患的方法，其中所述综合症、疾病或疾患是2型糖尿病、肥胖症和哮喘。该发明还涉及通过给哺乳动物施用公式I中至少一种化合物的治疗有效量来抑制CCR2活性的方法。

  公开号：

  US09062048B2

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Commercially Available CuO Catalyzed Hydrogenation of Nitroarenes Using Ammonia Borane as a Hydrogen Source
  作者：Jialei Du、Jie Chen、Hehuan Xia、Yiwei Zhao、Fang Wang、Hong Liu、Weijia Zhou、Bin Wang

  DOI：10.1002/cctc.201902391

  日期：2020.5.7

  dehydrogenation and nitroarenes hydrogenation has been reported as a novel strategy for the preparation of aromatic amines. However, the practical application of this strategy is subjected to the high‐cost and tedious preparation of supported noble metal nanocatalysts. The commercially available CuO powder is herein demonstrated to be a robust catalyst for hydrogenation of nitroarenes using ammonia borane

  串联氨硼烷脱氢和硝基芳烃氢化已被报道为制备芳族胺的新策略。然而，该策略的实际应用受到昂贵且繁琐的负载型贵金属纳米催化剂的制备的影响。本文证明可商购获得的CuO粉末是在温和条件下使用氨硼烷作为氢源用于硝基芳烃加氢的强力催化剂。通过这种方法可以获得许多胺（甚至是位阻，卤代和二胺）。这种单金属催化剂的特点是无载体，出色的化学选择性，低成本和高可回收性，这将有利于其在制备还原化学中的未来应用。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159854A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
• SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：AJINOMOTO CO., LTD.

  公开号：US20150051395A1

  公开（公告）日：2015-02-19

  Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

  提供的是具有特定化学结构的磺酰胺衍生物，在其末端有一个带有苯基或含杂原子的杂环基团作为取代基的磺酰胺基团，以及药用可接受的盐。这些化合物是具有卓越的α4整合素抑制作用的全新化合物。

表征谱图